ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0153

Obesity Is Associated with Higher Odds of Malignancy Development Among Dermatomyositis Patients
Abstract Number: 2234

Obesity, Adipokines, and Chronic and Persistent Pain in Rheumatoid Arthritis
Abstract Number: 0950

Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry
Abstract Number: 0677

Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
Abstract Number: 0601

Occupational Inhaled Agents Constitute Major Risk Factors for Rheumatoid Arthritis, Particularly in the Context of Genetic Predisposition and Smoking
Abstract Number: 0673

Occurrence and Severity of Bleeding in Adults with Immunogenic Thrombocytopenic Purpura with or Without Antiphospholipid Autoantibodies
Abstract Number: 0314

Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
Abstract Number: 0313

Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial
Abstract Number: 0230

Online Educational Module on Axial Spondyloarthritis Improves the Knowledge and Confidence of Non-rheumatology Providers
Abstract Number: 0215

Online Teaching of Hand Examination Using Student-recorded Videos and Remotely Delivered Feedback: A Pilot Study
Abstract Number: 0435

Onset of ANCA-associated Vasculitides in Systemic Sclerosis: Phenotype, Management and Outcomes
Abstract Number: 0073

Opioid and Pain Medication Prescribing by Rheumatologists for Medicare Part D Beneficiaries from 2013 to 2019
Abstract Number: 0402

Opioid Use and Healthcare Utilization in Adults with PsA and AS
Abstract Number: 0865

Opioid Use in Youth with Inflammatory Bowel Disease (IBD)-related Arthritis
Abstract Number: 0822

Optimal Use of Colchicine in COVID-19 Management from Rheumatologists’ Perspective: A Monocentric Observational Study During the SARS-CoV-2 Delta Variant Pandemic

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].